Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedJun 29, 2026
DataAggregated Company Financials
Companies9
  • 7D5.5%
  • 3M7.4%
  • 1Y32.2%
  • YTD9.4%

In the last week, the Pharma industry is up 5.5%, with Novartis leading the way, up 6.7%. Meanwhile, Dottikon ES Holding actually underperformed within the industry, shrinking 9.4% in the last week. This takes the industry's 12 month performance to a gain of 32%. As for the next few years, earnings are expected to grow by 10% per annum.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 29 Jun 2026CHF 577.2bCHF 123.0bCHF 25.1b36.7x23x4.7x
Wed, 27 May 2026CHF 562.1bCHF 121.2bCHF 24.8b39x22.7x4.6x
Fri, 24 Apr 2026CHF 553.4bCHF 121.4bCHF 25.2b37.9x22x4.6x
Sun, 22 Mar 2026CHF 526.7bCHF 121.5bCHF 25.2b36.5x20.9x4.3x
Tue, 17 Feb 2026CHF 601.2bCHF 119.3bCHF 24.3b36x24.8x5x
Thu, 15 Jan 2026CHF 588.5bCHF 121.3bCHF 21.6b36.3x27.3x4.9x
Sat, 13 Dec 2025CHF 543.3bCHF 121.1bCHF 21.5b33.2x25.2x4.5x
Mon, 10 Nov 2025CHF 488.1bCHF 121.7bCHF 21.6b32.3x22.6x4x
Wed, 08 Oct 2025CHF 512.1bCHF 120.3bCHF 21.0b33.8x24.4x4.3x
Fri, 05 Sep 2025CHF 498.4bCHF 120.8bCHF 21.1b31.6x23.7x4.1x
Sun, 03 Aug 2025CHF 459.5bCHF 120.6bCHF 20.9b23.2x22x3.8x
Tue, 01 Jul 2025CHF 447.1bCHF 117.0bCHF 18.9b24.8x23.7x3.8x
Thu, 29 May 2025CHF 437.5bCHF 119.3bCHF 19.3b25x22.7x3.7x
Sat, 26 Apr 2025CHF 426.6bCHF 118.1bCHF 18.5b25.2x23x3.6x
Mon, 24 Mar 2025CHF 487.4bCHF 121.8bCHF 19.2b29.7x25.4x4x
Wed, 19 Feb 2025CHF 476.6bCHF 122.6bCHF 19.2b23x24.9x3.9x
Fri, 17 Jan 2025CHF 445.2bCHF 119.7bCHF 21.4b18.5x20.8x3.7x
Sun, 15 Dec 2024CHF 420.5bCHF 118.6bCHF 21.2b17.9x19.8x3.5x
Tue, 12 Nov 2024CHF 442.0bCHF 117.8bCHF 21.1b18.9x20.9x3.8x
Thu, 10 Oct 2024CHF 454.4bCHF 115.6bCHF 19.4b21.5x23.4x3.9x
Sat, 07 Sep 2024CHF 459.3bCHF 114.4bCHF 19.2b22x23.9x4x
Mon, 05 Aug 2024CHF 458.6bCHF 115.3bCHF 19.5b22.6x23.5x4x
Wed, 03 Jul 2024CHF 435.1bCHF 116.8bCHF 19.8b33.8x21.9x3.7x
Fri, 31 May 2024CHF 406.4bCHF 116.7bCHF 19.8b42.4x20.5x3.5x
Sun, 28 Apr 2024CHF 394.0bCHF 113.6bCHF 20.0b37.3x19.7x3.5x
Tue, 26 Mar 2024CHF 386.3bCHF 111.8bCHF 19.4b37.7x20x3.5x
Thu, 22 Feb 2024CHF 386.1bCHF 110.3bCHF 19.7b24.4x19.6x3.5x
Sat, 20 Jan 2024CHF 413.6bCHF 120.4bCHF 18.8b27.2x22x3.4x
Mon, 18 Dec 2023CHF 394.8bCHF 120.6bCHF 18.8b24.6x21x3.3x
Wed, 15 Nov 2023CHF 389.5bCHF 121.9bCHF 19.0b23.9x20.5x3.2x
Fri, 13 Oct 2023CHF 411.0bCHF 121.9bCHF 18.7b26.5x22x3.4x
Sun, 10 Sep 2023CHF 401.2bCHF 112.5bCHF 18.0b47.1x22.3x3.6x
Tue, 08 Aug 2023CHF 410.6bCHF 111.5bCHF 17.9b48.1x23x3.7x
Thu, 06 Jul 2023CHF 421.3bCHF 115.3bCHF 18.9b36.4x22.3x3.7x
Price to Earnings Ratio

22.3x


Total Market Cap: CHF 421.3bTotal Earnings: CHF 18.9bTotal Revenue: CHF 115.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 22.5x.
  • The 3-year average PS ratio of 3.9x is lower than the industry's current PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 10% per year over the last three years.
  • Revenues for these companies have grown 2.2% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market2.22%
Healthcare5.29%
Pharma5.52%
Pharma5.52%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ROP Roche HoldingCHF 336.005.1%
+CHF 12.9b		28.4%PE20.8x
NOVN NovartisCHF 126.285.0%
+CHF 11.0b		31.3%PE21.1x
GALD Galderma GroupCHF 178.253.4%
+CHF 1.4b		50.4%PE84.3x
SDZ Sandoz GroupCHF 71.883.5%
+CHF 1.1b		65.5%PE42x
NWRN Newron PharmaceuticalsCHF 12.643.6%
+CHF 9.2m		89.8%PS14.9x

Latest News

ROP
CHF 336.00
Roche Holding
7D
5.1%
1Y
28.4%
Narrative Update • Jun 26

ROP: External Oncology Collaborations Will Likely Cap Near Term Upside

Analysts have updated their fair value estimate for Roche Holding to CHF 253.81 from CHF 295.00, reflecting refreshed assumptions on revenue growth, margins, and future P/E multiples in light of recent co-development agreements with partners such as Nurix Therapeutics. Analyst Commentary Recent Street research around Roche Holding and its partners gives you a mixed picture, with enthusiasm for the co-development agreements alongside more cautious voices highlighting execution and valuation risks.
SDZ
CHF 71.88
Sandoz Group
7D
5.8%
1Y
65.8%
Narrative Update • Jun 26

SDZ: Mixed Rating Shifts And Biosimilar Hub Investments Will Shape Future P/E

The analyst price target for Sandoz Group has been revised to CHF 70.74, reflecting updated views on fair value, revenue growth, profit margins, and future P/E after a mix of recent target cuts, target hikes, and an upgrade from major banks. Analyst Commentary Recent Street research on Sandoz Group shows a mix of optimism and restraint, with major banks adjusting their views on valuation, execution, and growth expectations.
NOVN
CHF 126.28
Novartis
7D
6.7%
1Y
31.3%
Narrative Update • Jun 26

NOVN: Oncology Pipeline Advances Will Drive Future Upside Potential

Analysts have revised their fair value estimate for Novartis to CHF144.47 from CHF138.41, reflecting updated assumptions around revenue growth, the discount rate, and future P/E. What’s in the News for Novartis Novartis agreed to a collaboration with Antares Therapeutics worth up to US$1.9b, including a US$105m upfront payment and potential US$1.8b in milestones, to discover and develop small molecule oncology therapies targeting historically undruggable cancers.
DESN
CHF 275.00
Dottikon ES Holding
7D
-9.4%
1Y
-7.7%
Analysis Article • Jun 24

Downgrade: Here's How Analysts See Dottikon ES Holding AG (VTX:DESN) Performing In The Near Term

Today is shaping up negative for Dottikon ES Holding AG ( VTX:DESN ) shareholders, with the analysts delivering a...
COPN
CHF 65.90
Cosmo
7D
-3.8%
1Y
15.8%
Narrative Update • Jun 22

COPN: European Dermatology Expansion Will Support CHF 160 Upside Potential

Analysts lifted their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple as key drivers of the change. What’s in the News for Cosmo Cosmo Pharmaceuticals N.V. reported that partners Glenmark Specialty S.A. and InfectoPharm launched Winlevi (clascoterone 1% cream) in key European markets, including Austria and Germany, following European Commission marketing authorization, according to recent company news.
GALD
CHF 178.25
Galderma Group
7D
3.4%
1Y
50.4%
Narrative Update • Jun 17

GALD: Rising Execution Bar And Rich P/E Will Likely Cap Future Share Upside

Analysts have raised the Galderma Group price target by CHF 5 to CHF 125.65, citing updated assumptions on fair value, revenue growth, profit margins and forward P/E that are consistent with a recent series of target increases from major banks. Analyst Commentary Recent Street research on Galderma Group points to a cluster of higher price targets, framed around updated assumptions for earnings quality, revenue mix and P/E levels.
CURN
CHF 23.40
Curatis Holding
7D
-1.3%
1Y
102.6%
ADXN
CHF 0.044
Addex Therapeutics
7D
-4.8%
1Y
-26.8%
NWRN
CHF 12.64
Newron Pharmaceuticals
7D
3.6%
1Y
84.8%
New Narrative • May 10

Still A Binary Phase III Bet on Evenamide

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.
BIOV
CHF 26.00
BioVersys
7D
-3.7%
1Y
-27.2%